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43%.
Conclusion: The 5-azacitidine is a treatment modality that
can improve or stabilize the disease, allowing time for
patients to reach alloHCT, with little toxicity, and can induce
response after post-alloHCT relapses.Table 1














Week 2 -6.5 (56) -7.7 (23) -11.6 (26) -9.5 (37) -4.5 (49)
Week 4 -8.7 (46) -9.4 (19) -8.6 (25) -12.4 (31) -3.3 (44)
Week 6 -10.1 (35) -7.0 (13) -12.0 (22) -1.9 (24) 1.3 (33)
Week 8 -18.5 (36) -2.2 (12) -11.3 (19) 5.8 (18) 12.2 (31)*
Week 10 -15.4 (21) -7.3 (5) -15.6 (13) 5.7 (14) 6.1 (21)*
Post-Week 1 -13.3 (57) -5.8 (19) -2.8 (25) 8.8 (35) 7.7 (49)*
* P< 0.05 t-test versus placebo379
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Background: CMX001 is an orally bioavailable, broad spec-
trum, lipid acyclic nucleoside phosphonate converted inside
cells to the active antiviral, cidofovir diphosphate. In the
preclinical toxicology program, GI AEs (diagnosed as gas-
tropathy and enteropathy; dose-related changes included
ﬂattening or loss of epithelial cells lining the lumen of the
small intestine on chronic dosing) were dose-limiting after
daily administration; however, therewere no GI AEs or gross/
microscopic gut changes when animals were dosed twice-
weekly (BIW) up to 9 months. Radiolabel studies in mice
conﬁrmed that CMX001 concentrates in the gut mucosa
more than in other tissues. In a Phase 2 dose-escalation study
(CMX001-201; ClinicalTrials.gov identiﬁer: NCT00942305)
evaluating CMX001 for CMV prophylaxis in allogeneic
hematopoietic stem cell transplant (HSCT) recipients, an
increased rate of profusewatery diarrheawas seen at 200mg
BIW and was considered dose-limiting in this population. A
program-wide safety monitoring and management plan that
included an option for dose interruption ( 2 weeks) in
subjects with  Grade 3 diarrhea was introduced. Subse-
quently, few subjects ( 10%) discontinued therapy because
of GI AEs, indicating that dose interruption is an appropriate
strategy to manage CMX001-associated GI AEs and to ach-
ieve effective CMV suppression in this population.
Methods: Serum chemistry data were evaluated for changes
in SA, a well-established marker of protein loss, to assess the
potential relationship to diarrhea. Abnormally low SA
concentrations were tabulated and the lowest value identi-
ﬁed through +1 week post treatment. A clinically meaningful
SA decrease was deﬁned as value  30 g/L (lower limit of
normal 33 g/L) and  4 g/L lower than baseline.
Results: Increased grade and/or duration of diarrhea corre-
lated with the decrease in SA concentrations over time as
shown in the Kaplan-Meier plots with data grouped by “low”
( 100mg/week) and “high” ( 200mg/week) CMX001 dose
vs. placebo. To rule out GI-GVHD (a common cause of diar-
rhea in HSCT recipients), the SA data from solid organ
transplant (SOT) patients treated with CMX001 in an
expanded access study (CMX001-350; ClinicalTrials.gov ID:
NCT01143181) were also evaluated. A similar timing of
decrease in SA concentrations was seen in these subjects
who are unlikely to have GVHD; urinalysis data also excluded
proteinuria as a cause.
Conclusions: Our clinical experience in the HSCT population
is consistent with preclinical ﬁndings. On chronic dosing,
CMX001 likely accumulates in the gut mucosa in some
patients and causes diarrhea that may be more pronounced
in individuals with other causes of diarrhea (eg, GI-GVHD).
Dose interruption gives the gut mucosa time to recover,
allowing subjects the opportunity to resume therapy.Monitoring SA changes in patients may provide an early and
objective indicator of potential drug-related GI AEs.380
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Background: CMX001 is an orally bioavailable, broad spec-
trum, lipid acyclic nucleoside phosphonate converted intra-
cellularly into the active antiviral, cidofovir diphosphate.
Unlike cidofovir, CMX001 is not a substrate for the anion
organic transporter and therefore is not concentrated in the
kidney.
Methods: Study CMX001-201 was a 9-11 week randomized,
placebo-controlled, double-blind, dose-escalation study
(evaluating 40 mg weekly [QW], 100 mg QW, 200 mg QW,
200mg twice-weekly [BIW] and 100mg BIW) of CMX001 for
the prevention of CMV infection post-HCT (ClinicalTrials.gov
ID: NCT00942305). Treatment was initiated at the time of
engraftment and continued until Week 13 post-HCT. Results
presented elsewhere have shown that CMX001, at various
doses, was active andwell tolerated in the prevention of CMV
infection or disease. Renal safety was assessed throughout
the duration of therapy using serum creatinine, urinalysis
and estimated glomerular ﬁltration rate (GFR, MDRD4
formula).
Results: 230 subjects were enrolled in the study; 59
received placebo and 171 received CMX001 at various
doses. 24 subjects (41%) on placebo and 77 subjects on
CMX001 (45%) had BK viruria prior to dosing. One subject
discontinued CMX001 40 mg QW due to acute renal failure;
no other subject discontinued from the study due to renal
adverse events. Results of calculated GFR by Study Cohort
and over time are presented in Table 1 below. Overall, renal
function tended to decline in placebo recipients while renal
function appeared to improve in subjects who received
CMX001 at 200 mg per week (either QW or divided into
2 BIW doses). The renal function decline in placebo
recipients appeared to be associated by the presence of
BK virus (BKV) in the urine at the time of treatment
commencement, while the proportion of subjects with
renal dysfunction was similar between BKV positive and
negative subjects among CMX001 recipients. There was
also a decreased incidence of microscopic hematuria in
BKV infected subjects treated with CMX001 as compared
to placebo recipients (6% vs. 25%).
Conclusions: CMX001 when administered at doses of 200
mg per week is not associated with signs of nephrotoxicity
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Further studies are warranted to assess the effect of CMX001
on BKV infection and its association with improved renal
function.381
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Background: Relapse is a major cause of treatment
failure of allogeneic stem cell transplant (SCT) for AML.
Most retrospective analyses describing the natural
history of relapse have not included recipients of T-cell
depleted transplants (TCD). We hypothesized that
response to therapy may be different in recipients of
TCD-SCT and that they may be more amenable to graft
versus leukemia effects. Thus we performed a retro-
spective analysis of our patients who relapsed after
a TCD-SCT.
Materials and Methods: From 2003 until 2012 we iden-
tiﬁed 42 patients with AML or MDS who relapsed after
a TCD-SCT at MSKCC. Patients were divided into four
groups based on management of relapse: supportive care
(n¼7), chemotherapy only (n¼17), chemotherapy plus DLI
(n¼8), and chemotherapy plus 2nd SCT (n¼10). Patient and
disease characteristics were compared across the four
groups using Fisher's exact test when categorical and the
Kruskal-Wallis test when continuous. Kaplan-Meier
methods were used to estimate survival probabilities and
the log-rank test evaluated differences in survival
between groups. Of the 10 patients who underwent
a second HSCT, 8 received T-cell replete and 2 underwent
another TCD-SCT.
Results: Across groups, there were no signiﬁcant differences
in sex (P ¼ .086), donor type (related vs unrelated;P ¼ .082),
percentage of blasts on relapse (median 25%;P¼ .317), and all
cause mortality (P ¼ .088). There was a statistically signiﬁ-
cant difference in the age of patients (P ¼ .010); youngest in
the chemo plus 2nd SCT group (median 41.5 yrs). The median
follow up time amongst survivors was 24.4 months (range,
13.6 - 69.8 m). There were 34 all cause mortality events; 4
due to NRM. Median survival for all groups was 16 months
(95% CI, 11.8-27.1). At 12 month follow up, the probability of
survival in supportive care, chemo only, chemo plus DLI, and
chemo plus 2nd SCT group were 43%, 41%, 88%, and 70%,
respectively. There was no statistically signiﬁcant difference
in overall survival (OS) between the groups (P ¼ .088).
Patients in the chemo plus DLI and chemo plus 2nd SCT
groups had the longest median OS of 28.6 months and 20.2
months, respectively. The median survival of patients who
received any salvage chemotherapy was 19.3 months (95% CI,
10.5-28.6) compared to 20.2 months (95% CI, 11.9-NA) for
those receiving chemo plus 2nd SCT (P ¼ .180). Complete
remission was achieved at any time in 5 patients in chemo
plus 2nd SCT, 3 patients in chemo plus DLI, and none of the
patients in chemo only group (P ¼ .003). Use of hypo-
methylating agents versus other salvage chemotherapy at
any point in treatment did not improve OS (P ¼ .745).
Conclusions: AML patients relapsing after a TCD-SCT can
be successfully treated, however long term disease
control is rare. Due to the small number of patients we
were not able to demonstrate statistically signiﬁcantdifference in outcomes among different salvage strat-
egies.382
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Introduction: Hemorrhagic Cystitis (HC) is a well-recog-
nized complication of hematopoietic stem cell trans-
plantation (HSCT) and is frequently associated with BK virus
reactivation. While self-limited, it is associated with signiﬁ-
cant morbidity. We hypothesized that serum PCR testing for
BK virus (BKV) before and after HSCT might predict devel-
opment of HC. To test our hypothesis, we conducted a retro-
spective analysis of patients who underwent allogeneic HSCT
from 2005 to 2012 at our institution.
Methods: We identiﬁed 162 patients who underwent allo-
geneic HSCT, 124 received myeloablative conditioning (MA)
and 38 received reduced intensity conditioning (RIC). The
MA regimen consisted of ﬂudarabine 50 mg/m2/day IV for 5
days and busulfan 3.2 mg/kg/day IV for 4 days with or
without total body irradiation (TBI) of 200 cGy/day for 2 days
(FB4 or FB4/TBI). The RIC regimen (FB2) consisted of ﬂudar-
abine 30 mg/m2/day IV for 5 days and busulfan 3.2 mg/kg/
day IV for 2 days. Ninety-six patients received matched
unrelated donor HSCT (MUD), 60 received matched related
donor (MRD) and 6 received unrelated cord blood (UCB).
Serum BKV screening was performed in 70 patients before
HSCT and in 63 patients at day +21. Patients with urinary
symptoms were tested for BKV in urine by PCR.
Results: Overall 36/162 patients (22%) developed HC.
Twenty-six of the 36 (72%) were positive for BKV. The
median time to development of HC from transplant was 37
days. The odds of developing HC was 4.2 fold higher in
patients receiving MA conditioning as compared to RIC (P ¼
.01; 95% CI¼1.22-14.69). The severity of HCwas not increased
with the addition of TBI (P ¼ .8). Graft source had no inﬂu-
ence on the incidence of HC (P ¼ .6). HC developed in 12/23
patients (52%) who were positive for BKV at day +21 and in
only 4/40 patients (10%) who were negative. Patients who
tested positive for BKV at day +21 were 9.8 times more likely
to develop HC than those who tested negative (P ¼ .0005;
95% CI ¼2.63-36.67). Testing at day +21 had a negative
predictive value (NPV) of 90% (p¼ < .0001; 95% CI¼76-97%).
Conclusion: HSCT using MA conditioning signiﬁcantly
increases the likelihood of developing HC compared to RIC.
While pre-HSCT serum testing of BKV had no signiﬁcant
predictive value, testing at day +21 helped identify a cohort
of patients at higher risk for development of HC. A clinical
trial of antiviral pre-emptive therapy might be warranted for
patients who test positive on day +21.383
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